Manuela Milani
Affiliations: | 2006-2009 | University of Oxford, Oxford, United Kingdom |
Google:
"Manuela Milani"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cazzaniga ME, Ademuyiwa F, Petit T, et al. (2023) Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer. Jnci Cancer Spectrum |
| Schettini F, De Bonis MV, Strina C, et al. (2023) Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib. Scientific Reports. 13: 11951 |
| Schettini F, Fontana A, Gattazzo F, et al. (2023) Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study. European Journal of Cancer (Oxford, England : 1990). 191: 112948 |
| Corona SP, Giudici F, Jerusalem G, et al. (2022) Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. Oncotarget. 13: 1307 |
| D'Angelo A, Giudici F, Chapman R, et al. (2022) Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study. Current Issues in Molecular Biology. 44: 4255-4267 |
| Garrigós L, Saura C, Martinez-Vila C, et al. (2021) COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology. 13: 17588359211053416 |
| Schettini F, Corona SP, Giudici F, et al. (2021) Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. Frontiers in Oncology. 11: 686776 |
| Bernocchi O, Sirico M, Corona SP, et al. (2021) Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. Pharmaceuticals (Basel, Switzerland). 14 |
| Sirico M, Bernocchi O, Sobhani N, et al. (2020) Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers. 12 |
| Schettini F, Sobhani N, Ianza A, et al. (2020) Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment |